Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

2

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor beta

2

Synaptic vesicular amine transporter

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

2017

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Open-angle glaucoma

2

Huntington's disease

1

Tardive dyskinesia

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Kakenyaku Kako

2

Auspex Pharmaceuticals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

DRUG BANK

3

EPA CompTox

3

EVMPD

3

FDA UNII

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIGLAUCOMA PREPARATIONS AND MIOTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Beta blocking agents

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DEUTETRABENAZINE

P341G6W9NB

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Synaptic vesicular amine transporter

Conditions:

Huntington's disease

Tardive dyskinesia

Deutetrabenazine (trade name Austedo) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease. The drug was developed by Auspex Pharmaceuticals and is being commercialized by...

Teva Pharmaceuticals. Deutetrabenazine is a deuterated derivative of tetrabenazine. The incorporation of deuterium in place of hydrogen at the sites of primary metabolism results in metabolic clearance being slowed, allowing less frequent dosing and better tolerability.

BEFUNOLOL

418546MT3A

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor beta

Conditions:

Open-angle glaucoma

Befunolol is a beta-adrenergic receptor blocker approved in Japan for the treatment of open-angle glaucoma. The current drug status is unknown.

BEFUNOLOL HYDROCHLORIDE

B03Z2VY37I

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor beta

Conditions:

Open-angle glaucoma

Befunolol is a beta-adrenergic receptor blocker approved in Japan for the treatment of open-angle glaucoma. The current drug status is unknown.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1